Safety and efficacy of port use for CAR T-cell infusion in large B-cell lymphoma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Safety and effectiveness of implanted ports for CAR T-cell infusion in large B-cell lymphoma

  • By

  • Zachary E. Hunzeker

  • Anath Lionel

  • Xiaowen Sun

  • Lei Feng

  • Sairah Ahmed

  • Amy Ayers

  • Michelly de Castro

  • Jaimole Varghese

  • Karla Ow

  • Taylor Cain

  • Minifrida Santiago

  • Sreekala Nair

  • Jeremy Ramdial

  • Elizabeth J. Shpall

  • Sattva S. Neelapu

  • Paolo Strati

  • October 28, 2026

Share

  • 1

    This single-center retrospective analysis included 504 patients with large B-cell lymphoma who received CAR T-cell infusion through a port (202 patients) or PICC/CVC (302 patients).

  • 2

    Line-associated infections and prolonged cytopenia rates were comparable between groups, while VTE was less frequent with ports than with PICC/CVCs (3.0% vs 9.3%; P = .006).

  • 3

    Day 30 and day 90 complete metabolic response rates did not differ significantly between the port and PICC/CVC groups.

  • 4

    Median progression-free and overall survival did not differ significantly between patients infused through ports and those infused through PICC/CVCs.

  • 5

    Among 128 patients assessed, CAR T-cell expansion measures did not differ significantly by access type at any assessed time point.

Original Source(s)

Related Content